| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C649049-5mg |
5mg |
期货  |
| |
| C649049-10mg |
10mg |
期货 |
|
| 规格或纯度 | ≥99% |
|---|---|
| 英文名称 | CP-346086 |
| 生化机理 | CP-346086 是一种强效口服活性微粒体甘油三酯转移蛋白（MTP）抑制剂，对人类和啮齿类动物 MTP 的 IC 50 为 2.0 nM。CP-346086 可降低体内血浆胆固醇和甘油三酯。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
CP-346086 is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC 50 of 2.0 nM for human and rodent MTP. CP-346086 can lower plasma cholesterol and triglycerides in vivo In Vitro CP-346086 (0.1-1000 nM) dose-dependently inhibits human MTP-mediated triglyceride transfer between vesicles with an IC 50 of 2.0 nM. CP-346086 (24 h) inhibits apolipoprotein B (apoB) and triglyceride secretion (IC 50 =2.6 nM) from Hep-G2 cells without affecting apoA-I secretion or lipid synthesis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo CP-346086 (1-100 mg/kg; oral gavage once daily for 2 weeks) reduces plasma total, VLDL, and LDL cholesterol and triglycerides in mice . CP-346086 (25 mg/kg; a single p.o.) results in an almost complete inhibition of Tyloxapol-induced triglyceride accumulation in fasted rats . CP-346086 (0.1-10 mg/kg; a single p.o.) reduces acute plasma triglyceride in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: B6CBAF1J mice Dosage: 1, 2, 10, 20, 100 mg/kg Administration: Oral gavage once daily for 2 weeks Result: Lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day. Form:Solid IC50& Target:IC50: 2.0 nM (MTP) |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | N-[2-(1H-1,2,4-triazol-5-ylmethyl)-3,4-dihydro-1H-isoquinolin-6-yl]-2-[4-(trifluoromethyl)phenyl]benzamide |
| INCHI | 1S/C26H22F3N5O/c27-26(28,29)20-8-5-17(6-9-20)22-3-1-2-4-23(22)25(35)32-21-10-7-19-14-34(12-11-18(19)13-21)15-24-30-16-31-33-24/h1-10,13,16H,11-12,14-15H2,(H,32,35)(H,30,31,33) |
| InChi Key | WNDIAFXQKOHFLV-UHFFFAOYSA-N |
| Smiles | C1CN(CC2=C1C=C(C=C2)NC(=O)C3=CC=CC=C3C4=CC=C(C=C4)C(F)(F)F)CC5=NC=NN5 |
| Isomeric SMILES | C1CN(CC2=C1C=C(C=C2)NC(=O)C3=CC=CC=C3C4=CC=C(C=C4)C(F)(F)F)CC5=NC=NN5 |
| PubChem CID | 9826309 |
| 分子量 | 477.5 |
| 溶解性 | DMSO : 100 mg/mL (209.43 mM; Need ultrasonic) |
|---|---|
| 分子量 | 477.500 g/mol |
| XLogP3 | 4.700 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 477.178 Da |
| 单同位素质量Monoisotopic Mass | 477.178 Da |
| 拓扑极表面积Topological Polar Surface Area | 73.900 Ų |
| 重原子数Heavy Atom Count | 35 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 714.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
首页
400-620-6333
